about
Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver DiseaseAdvances in Medications and Tailoring Treatment for Alcohol Use DisorderTargeting glutamate uptake to treat alcohol use disordersCare for hospitalized patients with unhealthy alcohol use: a narrative reviewP2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disordersRecent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders.A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats.Severity of drinking as a predictor of efficacy of the combination of ondansetron and topiramate in rat models of ethanol consumption and relapse.Should the reorganization of addiction-related research across all the National Institutes of Health be structural?--The devil is truly in the details.Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validityPharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors.Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humansObsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders.The pharmacogenetics of alcohol use disorderDisulfiram efficacy in the treatment of alcohol dependence: a meta-analysis.Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawalAlternative splicing of AMPA subunits in prefrontal cortical fields of cynomolgus monkeys following chronic ethanol self-administration.Dihydromyricetin as a novel anti-alcohol intoxication medication.Ivermectin reduces alcohol intake and preference in mice.Comparison of the effect of the GABAΒ receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in 3 different lines of alcohol-preferring rats.Pilot study of iPS-derived neural cells to examine biologic effects of alcohol on human neurons in vitro.Fostering multiple healthy lifestyle behaviors for primary prevention of cancer.Enhanced AMPA receptor activity increases operant alcohol self-administration and cue-induced reinstatementVoluntary wheel running reduces voluntary consumption of ethanol in mice: identification of candidate genes through striatal gene expression profilingAlcohol use disorders in the elderly: a brief overview from epidemiology to treatment options.Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems.Nicotine Increases Alcohol Intake in Adolescent Male RatsEfficacy and tolerability of baclofen in substance use disorders: a systematic review.The 5-HT7 receptor as a potential target for treating drug and alcohol abuse.Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.Sarcopenia in Alcoholic Liver Disease: Clinical and Molecular Advances.Rat animal models for screening medications to treat alcohol use disorders.Analysis of alcohol use disorders from the Nathan Kline Institute-Rockland Sample: Correlation of brain cortical thickness with neuroticism.Specific and nonspecific effects of naltrexone on goal-directed and habitual models of alcohol seeking and drinking.
P2860
Q26771090-F39181FC-47DC-44D5-A7E4-FB4F67E147D5Q26799814-954CA237-8F1A-4906-AB1F-C47A517C4F7AQ27002488-0F641F9A-15EB-46F3-BCAC-9A9A74FC29B3Q27004298-0FE94116-2C05-4650-8C84-99F0C6D39182Q27021285-3583BABF-CDDF-4DD4-8C56-8861979C73CCQ27024533-ACD11A9F-51E1-4C77-85F6-F1FDD9BCBC06Q28068256-D5677277-591C-4DD7-9971-3A379D3BCC00Q30408317-A9A6C164-026B-4A39-8E91-58861371DFE5Q30412006-8345EEE5-6795-463A-9F52-23456C7CF4D9Q30427534-52509DC8-6093-4FAB-BC3B-5A2CA387D477Q30447847-0EF85DB4-4112-450E-A9CB-9F2BCA8D0A4CQ33582063-0CEBEB20-633D-4EA7-B179-00A16FA06982Q34018001-1E390606-DBAD-4725-B937-12DC7DBC899DQ34018603-00099DBE-F3B0-47BF-8FDB-9A672731FFA1Q34184771-7C7AFB2B-49EA-4895-99B1-CACDD8274E04Q34256300-C66557DE-B637-4ABA-92AA-9DEABA105006Q34277168-AEB5BE4C-E25B-4136-8711-4388BFFCD68EQ34407070-6E13492E-1BFE-49A9-950C-5AC80C81C723Q34463974-E1D71033-0230-410C-9BCA-677FFA06C60AQ35092623-2EB74DC1-1A5E-438D-BCBC-EAFAB3E73C0DQ35565599-69FAE0A6-9ACA-48D5-8684-E7C13CC22217Q35589974-E3242AA5-30A0-433F-A983-424C81C6D037Q35646528-35FF5563-F7AF-4253-A227-E7E5F85DF453Q35797477-59B2E442-C862-457E-A768-485177ED89F4Q36024293-5EF3F5E0-39B9-483B-80CC-79BB9955D44FQ36095127-F9F375C0-A887-44EE-80AC-5266ADEAE3B8Q36179500-9750CC2C-0469-429D-AB71-B3F98CB8B054Q36224623-73B1DA8C-1D3D-4967-B3CF-B55804D02763Q36504079-0EBA494A-E35C-4BC0-B9D4-FAAF1B14D45DQ36963649-3723E7B3-7329-4B69-97BD-A517980F2052Q37207786-13A172F0-9DAE-4543-B7B4-3C0D0EB822FAQ37404222-7DC2D311-5CC4-4C85-9C95-B6893CE9DFE7Q37656941-34452F3B-D297-47CE-A8FC-C113E6D95677Q38115144-68AD3F48-1149-48EB-B844-94A80F09C64CQ38335136-9DB9D699-75D8-4C10-9AB3-CC34BEC00E35Q38718932-16830C77-0DF0-4717-8140-FA7754067282Q38756962-28677356-C06E-4005-AC3A-E5A905976C4AQ39142990-19EAC5F8-BF87-4157-B2E0-F3CFA2A6CD06Q39162968-9B9A7F1E-B1FA-4145-A402-8273B117A633Q40741139-87CA3050-4059-49B8-BA94-E7D81DCC934C
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Medication treatment of different types of alcoholism.
@ast
Medication treatment of different types of alcoholism.
@en
type
label
Medication treatment of different types of alcoholism.
@ast
Medication treatment of different types of alcoholism.
@en
prefLabel
Medication treatment of different types of alcoholism.
@ast
Medication treatment of different types of alcoholism.
@en
P2860
P1476
Medication treatment of different types of alcoholism.
@en
P2093
Bankole A Johnson
P2860
P304
P356
10.1176/APPI.AJP.2010.08101500
P407
P577
2010-06-01T00:00:00Z